{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039743","form_type":"8-K","ticker":"CNTN","cik":"0001861657","company_name":"Canton Strategic Holdings, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.168210+00:00","generated_at":"2026-06-08T17:32:51.221884+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tharimmune licenses clinical-stage TH104 for chronic pruritis; PBC Phase 2 trial planned","bullets":["Exclusive worldwide license from Avior for TH104 (AV104) and TH103; targets chronic pruritis in PBC, an orphan liver disease.","Upfront mid-six-digit fee plus installments; up to $24.25M in development milestones plus sales-based payments and royalties.","Plans to initiate Phase 2 trial in PBC patients within ~12 months after FDA alignment; expects top-line data thereafter.","TH104 uses buccal film delivery with dual mechanism on μ-opioid and κ-opioid receptors and IL-17 inhibition.","CEO Randy Milby says license agreement represents shift to clinical development focus."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039743","json":"https://secwatch.observer/filing/0001493152-23-039743.json","markdown":"https://secwatch.observer/filing/0001493152-23-039743.md","text":"https://secwatch.observer/filing/0001493152-23-039743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/0001493152-23-039743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:32:51.221884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bec6be74ff0ca71a8f2b3551040ef5714c3acf2","claim":"Canton Strategic Holdings, Inc. entered into Avior Patent License Agreement with Avior Inc. d/b/a Avior Bio, LLC valued at $24,250,000 (effective 2023-11-03).","evidence_excerpt":"Tharimmune, Inc. (the “Company”) entered into a patent license agreement (the “Avior Patent License Agreement”) with Avior Inc. d/b/a Avior Bio, LLC (“Avior”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223039743/0001493152-23-039743-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Avior Inc. d/b/a Avior Bio, LLC"},{"label":"Value","value":"$24,250,000"},{"label":"Effective","value":"2023-11-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}